DRKS00027556尚未招募2 期
Abatacept restores immune system equilibrium - ARISE
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •1. Diagnosis of CVID according to ESID/PAGID criteria or diagnosis of related disorders which fulfill the diagnostic criteria for CVID
- •2. A) Interstitial lung disease or granuloma diagnosed by chest CT positive for nodules, lines or ground-glass signs OR
- •B) Celiac-like enteropathy diagnosed by histologically proven lymphocytic enteropathy
- •3. Male and female patients of age 18 years and above
- •4. Signed written informed consent
- •5. Patient able to understand and willing to follow the protocol, including s.c. application and adequate storage of study drug
- •6. Patients receiving regular immunoglobulin replacement therapy with trough levels of IgG above 4g/l
- •7. Patients have failed steroid monotherapy (including topical steroids for enteropathy) for a minimum of three months or do not tolerate steroid treatment.
- •8. Need for intervention due to pulmonary manifestation measured by either reduced oxygen saturation, drop of oxygen saturation under exercise or reduced DLCOcSB
- •progress of interstitial lung disease measured by progressive
- •changes in the CT scan of the lung
- •Need for intervention due to gastrointestinal manifestation measured by stool frequency above three stools/day OR signs of malabsorption OR severe bloating
- •Marsh score of 3 in the duodenal histology
排除标准
- •1. Patient without legal capacity who is unable to understand the nature, significance and consequences of the study
- •2. Known diagnosis of a monogenic defect in CTLA-4 or LRBA
- •3. Other immunosuppressive therapy including biologicals beyond steroid at screening phase. Between treatment with other biologicals or DMARDs and start of abatacept trial treatment the wash out period of the pretreatment must be kept. In case of pretreatment with rituximab, therapy must be stopped at least 3 months before inclusion into trial.
- •4. Previous treatment with abatacept
- •5. Chronic or active infection or any major episode of infection requiring hospitalization or treatment with intravenous (i.v.) antibiotics within 30 days prior to baseline
- •6. Acute or uncontrolled chronic bacterial including tuberculosis or viral infection (including HIV, HBV; HCV, HEV, SARS-CoV2. Patients with a chronic Norovirus infection can be included).
- •7. Subjects who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Subjects who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
- •8. Receipt of a live replication-competent virus vaccine within 3 months prior to first application of trial medication.
- •9. Serious uncontrolled concomitant disease not caused by CVID.
- •10. Prior hematopoietic stem cell transplantation (HSCT) or HSCT planned within next 12 months
- •11. Known intolerance to study medication or any of the excipients
- •12. Current or planned pregnancy, nursing period; WOCBP need to keep anti-conceptive measures until 14 weeks after EOT.
研究者
相似试验
进行中（未招募）
1 期
Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive ArthralgiaEUCTR2014-000555-93-ESniversitätsklinikum Erlangen98
进行中（未招募）
1 期
Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive ArthralgiaPatients with ACPA (anti citrullinated peptide antibodies) positive arthralgia and OMERACT RAMRIS synovitis (synovialitis or tenosynovitis) or osteitis but without clinical arthritis, defined by joint swellingMedDRA version: 20.0Level: PTClassification code 10003239Term: ArthralgiaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000555-93-CZniversity Hospital Erlangen98
进行中（未招募）
1 期
Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive ArthralgiaPatients with ACPA (anti citrullinated peptide antibodies) positive arthralgia and OMERACT RAMRIS synovitis (synovialitis or tenosynovitis) or osteitis but without clinical arthritis, defined by joint swellingMedDRA version: 20.0Level: PTClassification code 10003239Term: ArthralgiaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000555-93-DEniversity Hospital Erlangen98
招募中
4 期
Can abatacept induce immunological remission under tight control in rheumatoid arthritis patient?Rheumatoid arthritisJPRN-UMIN000005570Department of Rheumatosurgery, Osaka City University Medical School50
招募中
不适用
Abatacept-based approach to cure of RARheumatoid ArthritisJPRN-UMIN000008756niversity of Occupational and Environmental Health, Japan40